High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy

Keisuke Shigeta, Takeo Kosaka, Shigehisa Kitano, Yota Yasumizu, Yasumasa Miyazaki, Ryuichi Mizuno, Toshiaki Shinojima, Eiji Kikuchi, Akira Miyajima, Hitoshi Tanoguchi, Shintaro Hasegawa, Mototsugu Oya

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The association of peripheral monocyte count and prostate cancer progression is not well characterized. Objective: Our aim was to investigate the prognostic value of absolute monocyte count (AMC), which is thought to modulate immune response in the tumor microenvironment, in castration-resistant prostate cancer (CRPC) patients treated with docetaxel chemotherapy. Methods: We retrospectively reviewed the medical records of 214 CRPC patients who received docetaxel therapy and were used as the training and validation set. Docetaxel at a dose of 75 mg/m2 was administered every 3 or 4 weeks. Clinicopathological factors and laboratory data were collected to assess the prognostic factors for overall survival (OS) and progression-free survival (PFS). Results: In the training set, the median age was 73.0 years, and the median prostate-specific antigen (PSA) value was 31.7 ng/ml at initial treatment. The median OS and PFS were 23.0 months (range 1.20–84.0) and 11.2 months (range 3.6–78.0), respectively. According to multivariable Cox regression analysis, AMC ≥400/uL, PSA level ≥20 ng/ml, and Hb

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalAnnals of Surgical Oncology
DOIs
Publication statusAccepted/In press - 2016 Jun 30

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy'. Together they form a unique fingerprint.

  • Cite this